Nektar Therapeutics (NKTR), Pfizer Inc. (PFE): What’s MannKind Corporation (MNKD) Really Worth?
This is close to the market cap that Bank of America's Steve Byrne thinks MannKind Corporation (NASDAQ:MNKD) is worth.
Posts Tagged ‘Novo Nordisk A S (NVO)’
Goldman Sachs Group, Inc. (GS), Novo Nordisk A/S (ADR) (NVO), Seaspan Corporation (SSW): Five Stocks Growing Their Dividends by 25% Per Year
Dividend investors would be wise to focus not just on a stock's current yield, but also on the long-term growth potential of its dividends.
MannKind Corporation (MNKD), Seattle Genetics, Inc. (SGEN), Eli Lilly & Co. (LLY): A Pharmacology Primer for Biotech Investors
In pharmacology, we don't only have to consider the actions of the drug on the body.
Express Scripts Holding Company (ESRX), Novo Nordisk A/S (ADR) (NVO), Walgreen Company (WAG): Don’t Mess With This 800-Pound Gorilla in the Pharma Space
Express Scripts Holding Company (NASDAQ:ESRX) -- the largest pharmacy benefit manager, or PBM, in America -- is also one of the most important companies in the health care ...
Will This Destroy MannKind Corporation (MNKD)?
The drug more closely mimics how the body secretes insulin after a meal to lower blood sugar, doing its job and leaving the bloodstream quickly.
MannKind Corporation (MNKD): To Infinity And Beyond?
The idea inspired me to issue my own questions about the company, using the questions as a crutch to explain my position.
Integra Lifesciences Holdings Corp (IART), NuVasive, Inc. (NUVA), CareFusion Corporation (CFN): A Solid Orthopedic Implants Manufacturer
The orthopedic implants market is a growing segment with increasing demand for extremities, spine, and orthobiologics.
Novo Nordisk A/S (ADR) (NVO), Dynavax Technologies Corporation (DVAX), Merck & Co., Inc. (MRK): Three Biggest FDA Rejections This Year (So Far)
At least the Food and Drug Administration is polite.
MannKind Corporation (MNKD), Eli Lilly & Co. (LLY): The Easiest Prediction in Biotech This Summer
Nothing is for certain in biotech, but it looks to me like the extended phase 3 program has an extremely high likelihood of coming up positive.
Celgene Corporation (CELG), Compugen Ltd. (USA) (CGEN): This Week in Biotech
With the SPDR S&P Biotech Index up 40% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
MannKind Corporation (MNKD), Novo Nordisk A/S (ADR) (NVO), Eli Lilly & Co. (LLY): A Good Drug That’s Too Risky to Buy
In a companion article a few days ago, I predicted that MannKind Corporation (NASDAQ:MNKD)'s extended phase 3 program for its inhaled insulin, Afrezza, is likely to produce ...
Arena Pharmaceuticals, Inc. (ARNA): Nothing to See Here, No Huge Sales Yet
The sales come from less than a month on the market -- the drug launched on June 11 and the quarter closed on June 30 -- and can't tell you anything about the long-term potential...
Novo Nordisk A/S (ADR) (NVO): Three Shocking Numbers on Diabetes’ Grim Future
Diabetes is one of the world's most dangerous and fastest-growing afflictions.
Will Arena Pharmaceuticals, Inc. (ARNA) Earnings Finally Explode Higher?
Arena Pharmaceuticals, Inc.
GlaxoSmithKline plc (ADR) (GSK), Novo Nordisk A/S (ADR) (NVO): China’s Growth Crisis Swings Into High Gear
It's been a long time since China's double-digit economic growth became the envy of nations across the world. Since then, the Chinese economy has slowed.
NutriSystem Inc. (NTRI), Novo Nordisk A/S (ADR) (NVO): Longer But Less Healthy Lives Will Benefit This Trio
NutriSystem Inc. (NASDAQ:NTRI), Novo Nordisk A/S (ADR) (NYSE:NVO), and Universal Health Services, Inc.
The Future of Sanofi SA (ADR) (SNY)’s Insulin Empire
Sanofi SA (ADR) (NYSE:SNY) appeared at the American Diabetes Association meeting last month, touting data for the new insulin U300 and a combo therapy involving its approved drugs...
Could This Safe Play Help Eli Lilly & Co. (LLY)?
At the American Diabetes Association meeting last month, Eli Lilly & Co. (NYSE:LLY) presented promising data for the GLP-1 agonist dulaglutide.
Could This Safe Play Help Eli Lilly & Co. (LLY)?
At the American Diabetes Association meeting last month, Eli Lilly & Co. (NYSE:LLY) presented promising data for the GLP-1 agonist dulaglutide.
Scripps Networks Interactive, Inc. (SNI), Smithfield Foods, Inc. (SFD), Novo Nordisk A/S (ADR) (NVO): How Paula Deen’s Mishap May Impact the Market
However you feel about celebrity chef Paula Deen, it's hard to ignore the impact one person has on the business world.
Is Now a Good Time to Buy Merck & Co., Inc. (MRK) Stock?
Merck & Co., Inc. (NYSE:MRK) has had its fair share of bad news recently. Shares have pulled back around 5% in June.
Wal-Mart Stores, Inc. (WMT), Novo Nordisk A/S (ADR) (NVO): Paula Deen Cooks Up Controversy With Corporate Backers
The trickle has become a torrent.
Sanofi SA (ADR) (SNY), Novo Nordisk A/S (ADR) (NVO), Johnson & Johnson (JNJ): Can Investors Bet on These 3 Pharma Companies?
It is expected that the death rate from diabetes will top 50% in the next ten years, which will make it a leading cause of death worldwide.
Is This What the Doctor Ordered for Eli Lilly & Co. (LLY)?
After the failure of its pipeline products for Alzheimer’s and rheumatoid arthritis, the drug giant Eli Lilly & Co. (NYSE:LLY) finally has some good news to report.
Why MannKind Corporation (MNKD) Is Poised to Pull Back
Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biopharmaceutical company MannKind Corporation...
The Cooper Companies, Inc. (COO), Valeant Pharmaceuticals Intl Inc (VRX): Tme to Buy This Defensive Growth Stock?
Everyone loves a defensive growth story, and there aren’t many better companies in the category than The Cooper Companies, Inc. (NYSE:COO).
BASF Se-spon Adr (BASFY), Codexis, Inc. (CDXS): World’s Largest Chemical Company Makes a Splash in Enzymes
It was only a matter of time.
Sanofi SA (ADR) (SNY), GlaxoSmithKline plc (ADR) (GSK), Johnson & Johnson (JNJ): 5 Costliest Microbes in Financial History
The field of synthetic biology is still in its infancy, with many of the most promising companies residing outside of public markets, but make no mistake: The bioeconomy is on...
VIVUS, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA) Are NOT The Newest Obesity Drug Player
VIVUS, Inc. (NASDAQ:VVUS) and Arena Pharmaceuticals, Inc.
Allergan, Inc. (AGN), Novo Nordisk A/S (ADR) (NVO): Should These Drug Companies Continue to Pay a Dividend?
Even a hardcore dividend addict such as I will admit that there are times when a company should hold off on paying a dividend.
Allergan, Inc. (AGN), Dr. Reddy’s Laboratories Limited (ADR) (RDY): Should These Drug Companies Pay a Dividend?
Even a hardcore dividend addict such as I will admit that there are times when a company should hold off on paying a dividend.
Becton, Dickinson and Co. (BDX), Novo Nordisk A/S (ADR) (NVO): Does The Healthcare Industry Mean Stability?
A leading medical technology company, Becton, Dickinson and Co. (NYSE:BDX)'s earnings were better than expected.
VIVUS, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA): A Belviq Battle
Things are beginning to look slightly up for obesity drugmaker VIVUS, Inc. (NASDAQ:VVUS) -- mere weeks before a competing drug from Arena Pharmaceuticals, Inc.
Merck & Co., Inc. (MRK), Novo Nordisk A/S (ADR) (NVO): Who Should You Buy?
Recently, I have focused in on some companies that play a major role in diabetic's lives like mine.
Invest In PepsiCo, Inc. (PEP) and The Coca-Cola Company (KO)?
Medscape is reporting the results of studies showing how just one soda each day can increase a person's chance of developing type 2 diabetes by as much as 25%.
Apple Inc. (AAPL), Novo Nordisk A/S (ADR) (NVO) & ‘The Most Sustainable Company in the World’
In January of 2012, Business Magazine released a list of the most sustainable companies in the world. You might be surprised to see who topped their list.
How to Profit From Increasing Obesity: Sanofi SA (ADR) (SNY), Novo Nordisk A/S (ADR) (NVO), Covidien plc (COV)
Funnily enough, I think that long term investors should be investing in the long term.
A Tough Road Ahead for This Big Pharma Partner: Codexis, Inc. (CDXS), Royal Dutch Shell plc (ADR) (RDS.A)
Bio-based enzyme producer Codexis, Inc. (NASDAQ:CDXS) reported financial results for the fourth quarter and full-year 2012 last week.
How Novo Nordisk A/S (ADR) (NVO) Will Deal With A Diabetes Delay: Sanofi SA (ADR) (SNY), Johnson & Johnson (JNJ)
Novo Nordisk A/S (ADR) (NYSE:NVO) recently got some bad news from the Food and Drug Administration: a request for additional information about a key insulin product.
Novo Nordisk A/S (ADR) (NVO): Still a Buy, Despite the Tresiba Setback
Shares of Novo Nordisk A/S (NYSE:NVO) are trying to recover from a recent sell-off that occurred after the FDA rejected its new drug Tresiba -- citing lack of a pre-approval ...
Hot Off the Press: VIVUS, Inc. (VVUS)’s Appeal for EU Approval Denied
Days after launching its obesity drug Qsymia in the U.S. last September, VIVUS, Inc.
Sanofi SA (ADR) (SNY)’s GLP-1 Accepted for Review by FDA
Sanofi SA (ADR) (NYSE:SNY) announced this week that the Food and Drug Administration began to review the company's once-daily type 2 diabetes injectable lixisenatide.
Pharmacyclics, Inc. (PCYC) Still on a Roll After Earnings Results
It's been a big week for Pharmacyclics, Inc. (NASDAQ:PCYC).
Can These 3 Stocks Be Resurrected?: Heckmann Corporation (HEK) and More
Lackluster trading was being blamed for the Dow Jones Industrial Average ticking down 21 points yesterday, gripped by ennui over both domestic and international financial woes...
What’s Moving These Biotech Stocks? – Novo Nordisk (NVO), Peregrine Pharmaceuticals (PPHM)
Typically, it doesn't take a lot for a stock to trade with gains/losses of more than 5% in a session; it can be caused by an analyst's remarks, sometimes it's caused by earnings...
Wall Street Loves Dynavax Technologies Corporation (DVAX). Should You?
Despite all of Wall Street's conflict and contention, a fortunate few companies enjoy unanimous support among professional analysts.
Allergan, Inc. (AGN): No Sign of a Slowdown at This Recession Resistant Company
I must confess I am finding the current market to be one of the most frustrating periods of my investing life.
The Expense Of Diabetes: Is It Worth It? Eli Lilly & Co. (LLY), Novo Nordisk A/S (NVO), Abbott Laboratories (ABT)
With studies showing 33% of Americans with diabetes or pre-diabetes, it is obvious that the industry should be booming.
Sanofi SA (SNY)’s New Diabetes Play Moves Forward
Sanofi SA (ADR) (NYSE:SNY) starts the week with a new European Union approval for the type 2 diabetes injectable Lyxumia.
Why Sanofi SA (NYSE:SNY) is Set for a Great 2013
Last year was a pretty good one for stockholders in Sanofi SA (NYSE:SNY), and the indications are that this year could be the same.
